Merck MRK, known as MSD outside the United States and Canada,
today announced the presentation of results from an integrated analysis
of patients with compensated liver cirrhosis (Child-Pugh class A) from
six Phase 2 and 3 clinical trials evaluating the efficacy and safety of
the investigational once-daily tablet elbasvir/grazoprevir1
(50mg/100mg) with or without ribavirin (RBV) in patients with chronic
hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Results from
the full analysis set (FAS) (n=402) demonstrate that treatment-naïve
patients with compensated liver cirrhosis who received
elbasvir/grazoprevir with or without RBV for 12 weeks achieved sustained
virologic response 12 weeks after the completion of treatment (SVR12, or
virologic cure) at rates of 90 percent (28/31) and 98 percent (135/138),
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in